Literature DB >> 26514741

Immunohistochemical expression of p16 in lipoblastomas.

Rocco Cappellesso1, Emanuele S G d'Amore2, Patrizia Dall'Igna3, Vincenza Guzzardo1, Elisa Vassarotto1, Massimo Rugge1, Rita Alaggio4.   

Abstract

Lipoblastoma (LB) is a rare benign adipocytic tumor of childhood occasionally showing histological similarities to myxoid liposarcoma (ML) or well-differentiated liposarcoma (WDL). p16 immunohistochemistry has proved to be useful in distinguishing various types of liposarcomas, in particular WDL from lipoma, with higher sensitivity and specificity than MDM2 and CDK4 immunohistochemistry. In this study, we reported the histologic features of a series of 30 LB with emphasis on the potential diagnostic pitfalls and investigated the immunohistochemical expression of p16. Moreover, p16 immunostaining was performed in 16 liposarcomas (11 WDL and 5 ML), 16 lipomas, and 16 cases of liponecrosis in order to evaluate its usefulness in the differential diagnosis of challenging lesions occurring in older children. Overall, p16 immunostaining was positive in 3 LBs and in 12 out of 16 liposarcomas (10 WDL and 2 ML), with a sensitivity of 75%, a specificity of 90%, a positive predictive value of 80%, and a negative predictive value of 87%. All lipomas were p16 negative, whereas 5 liponecroses were positive. Accounting altogether the benign lesions versus liposarcomas, p16 showed a sensitivity of 75%, a specificity of 87%, a positive predictive value of 60%, and a negative predictive value of 93%. Our data suggest that a negative p16 immunostaining may be helpful in excluding a liposarcoma when occurring in unusual clinical contexts, such as in adolescence or late recurrence. However, such finding should be interpreted with caution since also some liposarcomas lack p16 and occasional LBs are positive.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lipoblastoma; Liposarcoma; Myxoid liposarcoma; PLAG1; Well-differentiated liposarcoma; p16

Mesh:

Substances:

Year:  2015        PMID: 26514741     DOI: 10.1016/j.humpath.2015.08.019

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  5 in total

1.  Follow-up outcomes of pediatric patients who underwent surgical resection for lipoblastomas or lipoblastomatosis: a single-institution experience with a systematic review and meta-analysis.

Authors:  Dyda Dao; Anna J Najor; Philip Y Sun; Forough Farrokhyar; Christopher R Moir; Michael B Ishitani
Journal:  Pediatr Surg Int       Date:  2020-01-14       Impact factor: 1.827

2.  Diagnostic importance of clinicopathologic features and p16, CD34, MDM2 expression in differential diagnosis of adipocytic tumors.

Authors:  Eren Altun; Seher Yüksel; Gülşah Kaygusuz; Hüseyin Yusuf Yıldız
Journal:  Acta Orthop Traumatol Turc       Date:  2020-01       Impact factor: 1.511

Review 3.  Lipoblastoma: a clinicopathologic review of 23 cases from a major tertiary care center plus detailed review of literature.

Authors:  Jamshid Abdul-Ghafar; Zubair Ahmad; Muhammad Usman Tariq; Naila Kayani; Nasir Uddin
Journal:  BMC Res Notes       Date:  2018-01-17

Review 4.  Update of Pediatric Lipomatous Lesions: A Clinicopathological, Immunohistochemical and Molecular Overview.

Authors:  Eline Ameloot; Fleur Cordier; Jo Van Dorpe; David Creytens
Journal:  J Clin Med       Date:  2022-03-31       Impact factor: 4.241

5.  Lipoblastoma: Diagnosis and surgical considerations.

Authors:  Radu-Iulian Spătaru; Cătălin Cîrstoveanu; Dan-Alexandru Iozsa; Augustina Enculescu; Luminița Florentina Tomescu; Dragoș Șerban
Journal:  Exp Ther Med       Date:  2021-06-24       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.